# WuXi Biologics

Source: https://onco.cc/companies/wuxi-biologics/  
OnCo record `wuxi-biologics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates.

## Summary

Discovery, cell-line development and GMP manufacture of monoclonal and bispecific antibodies; WuXi XDC (listed separately in Hong Kong, 2268.HK) runs integrated ADC conjugation for a large share of clinical-stage ADCs from both Chinese and Western sponsors. Named in the US BIOSECURE Act; sold its Irish vaccine plant to Merck in 2025. The company behind much of the antibody supply for China's PD-1 and ADC boom.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: 药明生物; WuXi XDC
- Tags: china
- HQ: Wuxi / Shanghai
- Type: cro-services
- Website: https://www.wuxibiologics.com/
- Ticker: 2269.HK

## Sources

- Official website: https://www.wuxibiologics.com/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [GMP, inspections, Form 483s and warning letters](https://onco.cc/technologies/pharmaceutical-gmp-inspections/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- companies: [WuXi AppTec](https://onco.cc/companies/wuxi-apptec/)
- people: [Ge Li](https://onco.cc/people/li-ge/)
- bottlenecks: [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)

---
JSON: https://onco.cc/api/v1/entities/wuxi-biologics.json